For example, using the MMTV-PyMT mammary cancer model, Messenheimer and colleagues have shown in an elegant study that timing of the PD-1 blockade is critical to effective combination immunotherapy with anti-OX40 [46]. Here, TNFRSF4 is linked to breast cancer.